KR970706819A - 브라디키닌 관련 증상 억제 방법(Method of Inhibiting Conditions Associated with Bradykinin) - Google Patents

브라디키닌 관련 증상 억제 방법(Method of Inhibiting Conditions Associated with Bradykinin) Download PDF

Info

Publication number
KR970706819A
KR970706819A KR1019970702592A KR19970702592A KR970706819A KR 970706819 A KR970706819 A KR 970706819A KR 1019970702592 A KR1019970702592 A KR 1019970702592A KR 19970702592 A KR19970702592 A KR 19970702592A KR 970706819 A KR970706819 A KR 970706819A
Authority
KR
South Korea
Prior art keywords
bradykinin
excess
compound
inhibiting conditions
symptoms
Prior art date
Application number
KR1019970702592A
Other languages
English (en)
Inventor
로버트 프레데릭 쥬니어 브런즈
도날드 리차드 젤러트
제임스 제프리 하우버트
윌리암 헨리 워커 룬
Original Assignee
피터 쥐. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 쥐. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 쥐. 스트링거
Publication of KR970706819A publication Critical patent/KR970706819A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

하기 화학식 (Ⅰ)의 화합물 또는 그의 제약학적으로 허용가능한 염 또는 용매화물 유효량을 필요로 하는 인간에게 투여하는 것을 포함하는 과 브라디키닌 관련 생리학적 증상 억제하는 방법이 제공된다.
(상기 식에서, R1및 R3은 독립적으로 수소, -CH3,또는이고, (여기서 Ar은 임의로 치환된 페닐임)이고; R2는 피롤리디노, 헥사메틸렌이미노 및 피페리디노로 이루어지는 군으로부터 선택된다)

Description

브라디키닌 관련 증상 억제 방법(Method of Inhibiting Conditions Associated with Bradykinin)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 하기 화학식(1)의 화합물 또는 그의 제약학적으로 허용가능한 염 또는 용매화물 유효량을 과잉 브라디키닌 관련 생리학적 증상의 억제를 요하는 인간에게 투여하는 것을 포함하는 과잉 브라디키닌 관련 생리학적 증상을 억제하는 방법.
    (상기 식에서, R1및 R3은 독립적으로 수소, -CH3,이고, (여기서 Ar은 임의로 치환된 페닐임)이고; R2는 피롤리디노, 헥사메틸렌이미노 및 피페리디노로 이루어지는 군으로부터 선택된다.)
  2. 제1항에 있어서, 상기 화합물이 그의 염산염인 방법.
  3. 제1항에 있어서, 상기 투여가 예방적인 방법.
  4. 제1항에 있어서, 상기 화합물이 하기 화학식 (2)의 화합물 또는 그의 염산염인 방법.
  5. 제1항에 있어서, 과잉 브라디키닌 관련 증상이 통증 또는 통각인 방법.
  6. 제1항에 있어서, 과잉 브라디키닌 관련 증상이 염증인 방법.
  7. 제1항에 있어서, 과잉 브라디키닌 관련 증상이 비염인 방법.
  8. 제1항에 있어서, 과잉 브라디키닌 관련 증상이 천식인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019970702592A 1994-10-20 1995-10-19 브라디키닌 관련 증상 억제 방법(Method of Inhibiting Conditions Associated with Bradykinin) KR970706819A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/326,672 US5545641A (en) 1994-10-20 1994-10-20 Methods of inhibiting physiological conditions associated with an excess of bradykinin
US08/326,672 1994-10-20
PCT/US1995/013452 WO1996012491A1 (en) 1994-10-20 1995-10-19 Method of inhibiting conditions associated with bradykinin

Publications (1)

Publication Number Publication Date
KR970706819A true KR970706819A (ko) 1997-12-01

Family

ID=23273190

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970702592A KR970706819A (ko) 1994-10-20 1995-10-19 브라디키닌 관련 증상 억제 방법(Method of Inhibiting Conditions Associated with Bradykinin)

Country Status (16)

Country Link
US (1) US5545641A (ko)
EP (1) EP0782444A4 (ko)
JP (1) JPH10507760A (ko)
KR (1) KR970706819A (ko)
AU (1) AU714789B2 (ko)
CA (1) CA2203914A1 (ko)
CZ (1) CZ119197A3 (ko)
FI (1) FI971675A (ko)
HU (1) HUT77765A (ko)
IL (1) IL115614A (ko)
MY (1) MY113406A (ko)
NO (1) NO971794L (ko)
NZ (1) NZ296285A (ko)
RU (1) RU2181047C2 (ko)
WO (1) WO1996012491A1 (ko)
ZA (1) ZA958683B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545027B1 (en) * 1995-06-07 2003-04-08 Eli Lilly And Company Methods of modulating NF-kB transcription factor
EP0747051B1 (en) * 1995-06-07 2002-07-24 Eli Lilly And Company Treatment of diseases by inducing BEF-1 transcription factor
US6113876A (en) * 1996-01-29 2000-09-05 Eli Lilly And Company Methods of increasing sphincter competence
DE19620508A1 (de) * 1996-05-22 1997-11-27 Hoechst Ag Schwefelenthaltende heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
US6008232A (en) * 1997-08-20 1999-12-28 Eli Lilly And Company Methods for preventing headaches
HUP0200871A3 (en) 1999-05-04 2004-04-28 Strakan Int Ltd Androgen glycosides and androgenic activity thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4703053A (en) * 1985-10-28 1987-10-27 Warner-Lambert Company Benzothiophenes and benzofurans and antiallergic use thereof
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US4910317A (en) * 1987-07-14 1990-03-20 Warner-Lambert Company Benzofurans and benzothiophenes having antiallergic activity and method of use thereof
US4931459A (en) * 1987-07-14 1990-06-05 Warner-Lambert Company Method for treating acute respirator distress syndrome
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5441965A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
US5574047A (en) * 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair
US5521198A (en) * 1993-12-21 1996-05-28 Eli Lilly And Company Methods of inhibiting autoimmune diseases
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy

Also Published As

Publication number Publication date
NZ296285A (en) 2000-08-25
AU714789B2 (en) 2000-01-13
WO1996012491A1 (en) 1996-05-02
MY113406A (en) 2002-02-28
MX9702861A (es) 1997-07-31
NO971794D0 (no) 1997-04-18
JPH10507760A (ja) 1998-07-28
RU2181047C2 (ru) 2002-04-10
EP0782444A1 (en) 1997-07-09
EP0782444A4 (en) 2002-01-30
IL115614A (en) 1999-08-17
CA2203914A1 (en) 1996-05-02
NO971794L (no) 1997-05-22
FI971675A (fi) 1997-06-16
AU4003995A (en) 1996-05-15
CZ119197A3 (en) 1997-11-12
ZA958683B (en) 1997-04-14
US5545641A (en) 1996-08-13
HUT77765A (hu) 1998-08-28
IL115614A0 (en) 1996-01-19
FI971675A0 (fi) 1997-04-18

Similar Documents

Publication Publication Date Title
KR970706818A (ko) 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide)
KR950016732A (ko) 피부 및 질의 위축 억제방법
KR950016738A (ko) 알쯔하이머 질병의 억제 방법
KR950016744A (ko) 트롬빈을 저해하는 방법
KR950016746A (ko) 비-펩티드 타키키닌 수용체 길항물질
KR950016725A (ko) 폐 고혈압성 질병을 억제하는 방법
KR950010893A (ko) 자궁내막증 억제 방법
RU97108050A (ru) Способ ингибирования состояний, связанных с нейропептидом y
KR950010892A (ko) 자궁 섬유증 억제 방법
KR950016731A (ko) 지루 및 좌창의 억제 방법
KR950016723A (ko) 자가면역 질병의 억제 방법
KR950016745A (ko) 생리증상의 치료방법 및 이를 위한 조성물
KR950016730A (ko) 폐경기 후 증후군과 관련한 혈관 운동 증상 및 수반되는 심리학적 장애의 억제 방법
KR950016726A (ko) 기능부전성 자궁 출혈을 억제하는 방법
KR950016724A (ko) 폐경기 후 여성의 리비도를 증가시키는 방법
KR950016740A (ko) 조직의 불완전한 회복을 저해하는 방법
KR950010889A (ko) 혈관형성 및 혈관형성성 질병을 억제하는 방법
KR950010891A (ko) 내성 종양을 치료하는 방법
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
KR950010887A (ko) 연골 퇴화 억제 방법
KR950016734A (ko) 성적 조숙증의 억제방법
KR950016742A (ko) 폐경후 여성의 씨엔에스 질환을 억제하는 방법
KR950016743A (ko) 마이엘로퍼옥시다제 활성을 억제하는 방법
KR950016729A (ko) 유방 질환의 억제 방법
KR970705384A (ko) 골 보철 파손의 억제 방법(methods for inhibiting bone prosthesis degeneration)

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application